Secondary prevention of coronary artery disease with antimicrobials: Current status and future directions

American Journal of Cardiovascular Drugs

Volumn 2, Issue 2, 2002, Pages 107-118

  Muhlestein, Joseph B ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ATORVASTATIN; AZITHROMYCIN; CEPHALOSPORIN; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; MACROLIDE; METRONIDAZOLE; NALIDIXIC ACID; OMEPRAZOLE; PENICILLIN G; PLACEBO; PRAVASTATIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; ROXITHROMYCIN; SULFONAMIDE; TETRACYCLINE;

ADULT; ALPHA HEMOLYTIC STREPTOCOCCUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL THERAPY; ATHEROSCLEROSIS; CAUSE OF DEATH; CHLAMYDOPHILA PNEUMONIAE; COMPLICATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; ERADICATION THERAPY; FAMILY HISTORY; FOLLOW UP; HEART INFARCTION; HELICOBACTER PYLORI; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHESIS; INFECTION; MAJOR CLINICAL STUDY; MORTALITY; NONHUMAN; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; RABBIT; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SHORT COURSE THERAPY; SMOKING; STATISTICAL ANALYSIS; TREATMENT OUTCOME; WESTERN HEMISPHERE;

EID: 0036265891     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200202020-00004     Document Type: Review

References (133)

1. Dyslipidemia and other risk factors for CAD
2. Shattuck lecture - Cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities
3. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR
4. Serological evidence of an association of a novel chlamydia, TWAR, with chronic CHD and acute MI
5. Chlamydia pneumoniae serology: Importance of methodology in patients with CHD and healthy individuals
6. Circulating immune complexes containing chlamydial lipopolysaccharide in acute MI
7. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated CAD
8. Chronic Chlamydia pneumoniae infection as a risk factor for CHD in the Helsinki heart study
9. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated CAD
10. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic CHD
11. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis
12. Serological response to Chlamydia pneumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques
13. Chlamydia pneumoniae infection as a risk factor in acute MI
14. Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early CAD
15. Chlamydia pneumoniae: Risk factors for seropositivity and association with CHD
16. Association of Helicobacter pylori and Chlamydia pneumoniae infections with CHD and cardiovascular risk factors
17. Chlamydia pneumoniae and acute arterial thrombotic disease
18. Association of Chlamydia pneumoniae and acute CHD events in non-insulin dependent diabetic and non-diabetic subjects in Finland
19. Association of chlamydial infection with cerebrovascular disease
20. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of MI
21. A possible association of Chlamydia pneumoniae infection and acute MI in patients younger than 65 years of age
22. Chlamydia pneumoniae and acute MI in Jerusalem
23. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for CAD and MI
24. Chlamydia pneumoniae is a risk factor for CHD in symptom-free elderly men, but Helicobacter pylori and cytomegalovirus are not
25. Association of chronic infection of Chlamydia pneumoniae and CHD in the Japanese
26. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: A prospective study in middle-aged to elderly men with treated hypertension
27. Lack of association between prior infection with Chlamydia pneumoniae and acute or chronic CAD
28. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future MI
29. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident MI and CHD death in older adults: The Cardiovascular Health Study
30. Are morphological or functional changes in the carotid artery wall associated with Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, or herpes simplex virus infection?
31. Infections, immunity, and atherosclerosis: Associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis
32. Possible role of chronic infection with Chlamydia pneumoniae in Japanese patients with acute MI
33. High prevalence of seropositivity for antibodies to Chlamydia-specific lipopolysaccharide in patients with acute coronary syndrome
34. Hyperinsulinemia, lipoprotein (a), and Chlamydia pneumoniae antibodies: Are they risk factors or serologic predictors for progression of CAD?
35. Seropositivity to chlamydial lipopolysaccharide and Chlamydia pneumoniae, systemic inflammation and stable CAD: Negative results of a case-control study
36. Serologic and histopathologic study of Chlamydia pneumoniae infection in atherosclerosis: A possible pathogenetic mechanism of atherosclerosis induced by Chlamydia pneumoniae
37. The relation between Chlamydia pneumoniae infection and abdominal aortic aneurysm: Case-control study
38. Chlamydia pneumoniae infection and mortality from ischaemic heart disease: Large prospective study
39. Chlamydia pneumoniae seropositivity is associated with carotid artery intima-media thickness
40. Chlamydia pneumoniae and the risk of first ischemic stroke: The Northern Manhattan Stroke Study
41. Seropositivity against Chlamydia pneumoniae in patients with coronary atherosclerosis
42. Association between C-reactive protein, anti-Chlamydia pneumoniae antibodies, and vascular function in healthy adults
43. Previous exposure to Chlamydia pneumoniae, Helicobacter pylori and other infections in Canadian patients with ischemic heart disease
44. The significance of Chlamydia pneumoniae in symptomatic carotid stenosis
45. Chlamydia pneumoniae infection and its association with CHD and cardiovascular risk factors in a sample South Asian population
46. Association of seropositivity for antibody to Chlamydia-specific lipopolysaccharide and CAD in Japanese men
47. C-reactive protein and chronic Chlamydia pneumoniae infection: Long-term predictors for cardiovascular disease and survival in patients on peritoneal dialysis
48. Enhanced progression of early carotid atherosclerosis is related to Chlamydia pneumoniae (Taiwan acute respiratory) seropositivity
49. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atherosclerotic plaques
50. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease
51. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis
52. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain
53. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries
54. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old)
55. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery
56. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues
57. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms
58. Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy
59. Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction
60. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen
61. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: Evaluation of the innocent bystander hypothesis
62. Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms
63. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis
64. Chlamydia pneumoniae in atheroma: Consideration of criteria for causality
65. Endovascular presence of Chlamydia pneumoniae DNA is a generalized phenomenon in atherosclerotic vascular disease
66. Poor correlation between microimmunofluorescence serology and polymerase chain reaction for detection of vascular Chlamydia pneumoniae infection in CAD patients
67. Chlamydia pneumoniae in coronary and iliac arteries of Japanese patients with atherosclerotic cardiovascular diseases
68. Failure to detect Chlamydia pneumoniae in atherosclerotic plaques of Australian patients
69. Failure to demonstrate Chlamydia pneumoniae in symptomatic abdominal aortic aneurysms by a nested polymerase chain reaction (PCR)
70. Distribution of Chlamydia pneumoniae infection in the atherosclerotic carotid artery
71. The prevalence of Chlamydia pneumoniae in atherosclerotic and nonatherosclerotic blood vessels of patients attending for redo and first time coronary artery bypass graft surgery
72. Chlamydia pneumoniae in atherosclerotic middle cerebral artery
73. Detection of Chlamydia pneumoniae bacteremia in patients with symptomatic coronary atherosclerosis
74. Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in peritoneal dialysis patients
75. Circulating nucleic acids of Chlamydia pneumoniae and cytomegalovirus in patients undergoing coronary angiography
76. Circulating Chlamydia pneumoniae DNA as a predictor of CAD
77. Detection of Chlamydia pneumoniae DNA in CD3+ lymphocytes from healthy blood donors and patients with CAD
78. High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors
79. Chlamydia pneumoniae DNA detection in peripheral blood mononuclear cells is predictive of vascular infection
80. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model
81. Antibiotics effects in a rabbit model of Chlamydia pneumoniae-induced atherosclerosis
82. Collaborative multidisciplinary workshop report: What questions regarding the role of chlamydia pneumoniae in athersclerosis and cardiovascular disease need to be addressed utilizing animal models?
83. Chlamydia pneumoniae infection significantly exacerbates aortic atherosclerosis in an LDLR-/- mouse model within six months
84. Mouse models of C. pneumoniae infection and atherosclerosis
85. Endothelial dysfunction after repeated Chlamydia pneumoniae infection in apolipoprotein E-knockout mice
86. Chlamydia pneumoniae does not increase atherosclerosis in the aortic root of apolipoprotein E-deficient mice
87. Chlamydia pneumoniae induces inflammatory changes in the heart and aorta of normocholesterolemic C57BL/6J mice
88. Comparative genomes of Chlamydia pneumoniae and C. trachomatis
89. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells
90. Oxidized low density lipoproteins alter macrophage lipid uptake, apoptosis, viability and nitric oxide synthesis
91. Induction of macrophage foam cell formation by Chlamydia pneumoniae
92. Chlamydia species infect human vascular endothelial cells and induce procoagulant activity
93. Vascular heat shock protein expression in response to stress: Endocrine and autonomic regulation of this age-dependent response
94. Role of heat shock protein 65/60 in the pathogenesis of atherosclerosis
95. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression
96. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages
97. Chlamydia pneumoniae inhibits apoptosis in human peripheral blood mononuclear cells through induction of IL-10
98. Chlamydia infections and heart disease linked through antigenic mimicry
99. Microbiology of Helicobacter pylori
100. Helicobacter pylori infection
101. Helicobacter pylori: Beyond peptic ulcer disease
102. Detection of Helicobacter pylori in human carotid atherosclerotic plaques
103. Relation of Helicobacter pylori infection and CHD
104. Chronic infections and CHD: Is there a link?
105. Risk factors for CHD and infection with Helicobacter pylori: Meta-analysis of 18 studies
106. Association of the oral flora with important medical diseases
107. Life below the gum line: Pathogenic mechanisms of Porphyromonas gingivalis
108. A bacterial sensitivity test to determine the effectiveness of minocycline HCI (Minocin), erythromycin (Erythrocin) and ampicillin (Ampicin) on the predominant microorganisms present in a diseased periodontium
109. Position paper of The American Academy of Periodontology: Periodontal disease as a potential risk factor for systemic diseases
110. Association between dental health and acute MI
111. Dental disease and risk of CHD and mortality
112. Periodontal disease and cardiovascular disease
113. An association between periodontal disease and peripheral vascular disease
114. Periodontal disease and risks of cardiovascular disease
115. Periodontal disease and CHD risk
116. Antibiotics in the prevention and treatment of CHD
117. Antibiotics and risk of subsequent first-time acute MI
118. Lack of association between first MI and past use of erythromycin, tetracycline, or doxycycline
119. Acute MI and prior antibiotic use
120. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of MI
121. Randomized trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study
122. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes: The final report of the ROXIS Study
123. Randomized secondary prevention trial of azithromycin in patients with CAD and serological evidence for Chlamydia pneumoniae infection. The azithromycin in CAD: Elimination of myocardial infection with chlamydia (ACADEMIC) study
124. Randomized secondary prevention trial of azithromycin in patients with CAD: Primary clinical results of the ACADEMIC Study
125. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): A randomised, double-blind, placebo-controlled trial
126. Antibiotics against Chlamydia pneumoniae and helicobacter pyloris redyce further cardiovascular events in patients with acute coronary syndromes
127. Rationale and design of secondary prevention trial of antibiotic use in patients after myocardial infarction: The WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorder(s) trial
128. Weekly interventions with zithromax for atherosclerosis and its related disorders
129. The effect of short-term treatment with azithromycin on recurrent ischemic events in patients with acute coronary syndrome
130. Description and status of the azithromycin and coronary events study (ACES)
131. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment
132. Chronic infection and CAD
133. Collaborative multidisciplinary workshop report: Clinical antimicrobial trials for primary and secondary prevention of atherosclerotic cardiovascular disease